Resona Asset Management Co. Ltd. bought a new stake in Illumina, Inc. (NASDAQ:ILMN - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 45,316 shares of the life sciences company's stock, valued at approximately $6,065,000.
A number of other institutional investors have also added to or reduced their stakes in the company. Norges Bank bought a new position in Illumina in the 4th quarter valued at about $228,714,000. WCM Investment Management LLC grew its holdings in Illumina by 26.6% during the fourth quarter. WCM Investment Management LLC now owns 4,129,855 shares of the life sciences company's stock worth $551,625,000 after buying an additional 867,673 shares in the last quarter. Pictet Asset Management Holding SA lifted its stake in Illumina by 245.7% during the 4th quarter. Pictet Asset Management Holding SA now owns 1,182,454 shares of the life sciences company's stock valued at $158,011,000 after acquiring an additional 840,423 shares in the last quarter. ARK Investment Management LLC bought a new stake in shares of Illumina in the 4th quarter worth $91,714,000. Finally, AKO Capital LLP bought a new stake in Illumina in the 4th quarter worth about $66,185,000. 89.42% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
A number of analysts recently commented on the company. Barclays decreased their price target on Illumina from $100.00 to $77.00 and set an "underweight" rating for the company in a research report on Thursday. Robert W. Baird reduced their price target on shares of Illumina from $127.00 to $90.00 and set a "neutral" rating for the company in a research report on Wednesday, March 5th. Morgan Stanley decreased their price objective on shares of Illumina from $150.00 to $136.00 and set an "equal weight" rating for the company in a report on Tuesday, February 11th. Hsbc Global Res cut shares of Illumina from a "strong-buy" rating to a "hold" rating in a research note on Friday, February 28th. Finally, Canaccord Genuity Group reduced their target price on shares of Illumina from $135.00 to $115.00 and set a "hold" rating for the company in a research report on Tuesday, March 11th. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $138.70.
View Our Latest Stock Analysis on Illumina
Illumina Stock Up 1.5 %
Illumina stock traded up $1.15 during mid-day trading on Monday, hitting $75.93. The company had a trading volume of 401,227 shares, compared to its average volume of 2,261,026. Illumina, Inc. has a 12 month low of $68.70 and a 12 month high of $156.66. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63. The stock's 50 day moving average price is $88.58 and its two-hundred day moving average price is $122.25. The company has a market capitalization of $12.03 billion, a PE ratio of -9.89, a price-to-earnings-growth ratio of 1.60 and a beta of 1.38.
Illumina (NASDAQ:ILMN - Get Free Report) last issued its earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. As a group, sell-side analysts anticipate that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.
About Illumina
(
Free Report)
Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
Recommended Stories
Before you consider Illumina, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Illumina wasn't on the list.
While Illumina currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
